Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 10/20 | 1.00 |
| ▸ | EYA3 | Q99504 | 7/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.65 |
| ▸ | TTR | P02766 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.54 |
| ▸ | PGR | P06401 | 2/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.54 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | DRD1 | P21728 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1287500 | 0.90 | SLC22A12 (0.86) | SLC22A12EYA3CYP2C9TTRCYP2C19 | |
| SCHEMBL1287929 | 0.89 | SLC22A12 (0.80) | SLC22A12EYA3CYP2C9TTRLMNA | |
| SCHEMBL6336521 | 0.89 | SLC22A12 (0.80) | SLC22A12EYA3CYP2C9TTRLMNA | |
| SCHEMBL1287413 | 0.88 | SLC22A12 (1.00) | SLC22A12EYA3CYP2C9TTRLMNA | |
| SCHEMBL1287502 | 0.87 | SLC22A12 (1.00) | SLC22A12EYA3CYP2C9LMNAHTT | |
| SCHEMBL5020570 | 0.86 | EYA3 (0.77) | SLC22A12EYA3CYP2C9TTRLMNA | |
| Benzarone SCHEMBL29576057 | 0.85 | EYA3 (1.00) | SLC22A12EYA3CYP2C9TTRLMNA | |
| Benzarone SCHEMBL555497 | 0.85 | EYA3 (1.00) | SLC22A12EYA3CYP2C9TTRLMNA | |
| SCHEMBL1287499 | 0.85 | SLC22A12 (1.00) | SLC22A12EYA3CYP2C9TTRLMNA | |
| SCHEMBL11752573 | 0.85 | SLC22A12 (0.74) | SLC22A12EYA3CYP2C9TTRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130312-A1 | INHIBITORS OF EYA3-PROTEIN TYROSINE PHOSPHATASE IN DNA DAMAGE REPAIR SIGNALING OF PULMONARY ARTERIAL HYPERTENSION | CHILDRENS HOSPITAL MED CT (US) | 2021-05-06 | — | — | US | disclosed |
| US-10221151-B2 | Use of small molecule inhibitors targeting EYA tyrosine phosphatase | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2019-03-05 | — | — | US | disclosed |
| US-10005750-B2 | Developing potent urate transporter inhibitors: compounds designed for their uricosuric action | J-PHARMA CO., LTD. (JP) | 2018-06-26 | — | — | US | disclosed |
| US-9962362-B2 | Use of small molecule inhibitors targeting EYA tyrosine phosphatase | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2018-05-08 | — | — | US | disclosed |
| US-9962362-B2 | Use of small molecule inhibitors targeting EYA tyrosine phosphatase | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170349562-A1 | USE OF SMALL MOLECULE INHIBITORS TARGETING EYA TYROSINE PHOSPHATASE | CHILDREN'S HOSPITAL MEDICAL CENTER | 2017-12-07 | — | — | US | disclosed |
| US-20170349562-A1 | USE OF SMALL MOLECULE INHIBITORS TARGETING EYA TYROSINE PHOSPHATASE | CHILDREN'S HOSPITAL MEDICAL CENTER | 2017-12-07 | — | — | US | disclosed |
| US-9725430-B2 | Use of small molecule inhibitors targeting EYA tyrosine phosphatase | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725430-B2 | Use of small molecule inhibitors targeting EYA tyrosine phosphatase | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160052904-A1 | USE OF SMALL MOLECULE INHIBITORS TARGETING EYA TYROSINE PHOSPHATASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-25 | — | — | US | disclosed |
| US-20160052904-A1 | USE OF SMALL MOLECULE INHIBITORS TARGETING EYA TYROSINE PHOSPHATASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-25 | — | — | US | disclosed |
| US-20140128460-A1 | USE OF SMALL MOLECULE INHIBITORS TARGETING EYA TYROSINE PHOSPHATASE | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128460-A1 | USE OF SMALL MOLECULE INHIBITORS TARGETING EYA TYROSINE PHOSPHATASE | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2014-05-08 | — | — | US | disclosed |
| US-20130225673-A1 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | J-PHARMA CO., LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
| WO-2012048058-A2 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | J-PHARMA CO., LTD. (JP) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349562-A1 | USE OF SMALL MOLECULE INHIBITORS TARGETING EYA TYROSINE PHOSPHATASE | EYA2, EYA3, PTPRO | SLC22A12 3718/4885EYA3 2/4885CYP2C9 4758/4885 |
| US-10005750-B2 | Developing potent urate transporter inhibitors: compounds designed for their uricosuric action | SLCO2B1, SLCO2A1, SLC10A6 | SLC22A12 19/4885EYA3 4828/4885CYP2C9 203/4885 |
| US-20140128460-A1 | USE OF SMALL MOLECULE INHIBITORS TARGETING EYA TYROSINE PHOSPHATASE | EYA2, EYA3, PTPRO | SLC22A12 3718/4885EYA3 2/4885CYP2C9 4758/4885 |
| US-10221151-B2 | Use of small molecule inhibitors targeting EYA tyrosine phosphatase | EYA2, EYA3, PTPRO | SLC22A12 3718/4885EYA3 2/4885CYP2C9 4758/4885 |
| US-20130225673-A1 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | SLCO2B1, SLCO2A1, SLC10A6 | SLC22A12 19/4885EYA3 4828/4885CYP2C9 203/4885 |
| US-20210130312-A1 | INHIBITORS OF EYA3-PROTEIN TYROSINE PHOSPHATASE IN DNA DAMAGE REPAIR SIGNALING OF PULMONARY ARTERIAL HYPERTENSION | EYA3, EYA2, LIG3 | SLC22A12 4469/4885EYA3 1/4885CYP2C9 4189/4885 |
| US-20160052904-A1 | USE OF SMALL MOLECULE INHIBITORS TARGETING EYA TYROSINE PHOSPHATASE | EYA2, EYA3, PTPRJ | SLC22A12 1883/4885EYA3 2/4885CYP2C9 4779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.